Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Johnson, Peter ^a   Greiner, Wolfgang ^b   Al Dakkak, Imad ^c   Wagner, Samuel ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b BIELEFELD UNIVERSITY   (Germany)

^c PAREXEL INTERNATIONAL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOMODULATING AGENT; IPILIMUMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; HUMAN; KIDNEY CARCINOMA; LONG TERM SURVIVAL; MELANOMA; META ANALYSIS (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; BIOASSAY; DISEASE FREE SURVIVAL; NEOPLASMS; PATHOLOGY;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84934325277     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/865101     Document Type: Review

References (43)

1. R. Sridhara, J. R. Johnson, R. Justice, P. Keegan, A. Chakravarty, and R. Pazdur, "Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007", Journal of the National Cancer Institute, vol. 102, no. 4, pp. 230-243, 2010.
2. S. A. Rosenberg, "Raising the bar: the curative potential of human cancer immunotherapy", Science Translational Medicine, vol. 4, no. 127, Article ID 127ps8, 2012.
3. D. Schadendorf, F. S. Hodi, C. Robert et al., "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma", in Proceedings of the European Cancer Congress (ECC'13), Abs 24LBA, 2013.
4. J. M. Kirkwood, L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone, "Immunotherapy of cancer in 2012", CA: A Cancer Journal for Clinicians, vol. 62, no. 5, pp. 309-335, 2012.
5. O. J. Finn, "Immuno-oncology: understanding the function and dysfunction of the immune system in cancer", Annals of Oncology, vol. 23, supplement 8, pp. viii6-viii9, 2012.
6. J. D. Wolchok, F. S. Hodi, J. S. Weber et al., "Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma", Annals of the New York Academy of Sciences, vol. 1291, no. 1, pp. 1-13, 2013.
7. D. McDermott, J. Haanen, T. T. Chen, P. Lorigan, and S. O'Day, "Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)", Annals of Oncology, vol. 24, no. 10, pp. 2694-2698, 2013.
8. F. S. Hodi, S. L. Topalian, J. Brahmer et al., "Survival and longterm safety in patients with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)", in Proceedings of the European Cancer Congress (ECC'13), Abs 880P, 2013.
9. O. Hamid, C. Robert, A. Daud et al., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", The New England Journal of Medicine, vol. 369, no. 2, pp. 134-144, 2013.
10. J. C. Soria, C. Cruz, R. Bahleda et al., "Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)", in Proceedings of the CC Congress, Abstract 3408, 2013.
11. D. N. Lakdawalla, J. A. Romley, Y. Sanchez, J. R. Maclean, J. R. Penrod, and T. Philipson, "How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies", Health Affairs, vol. 31, no. 4, pp. 676-682, 2012.
12. M. Othus, B. Barlogie, M. L. Le Blanc, and J. J. Crowley, "Cure models as a useful statistical tool for analyzing survival", Clinical Cancer Research, vol. 18, no. 14, pp. 3731-3736, 2012.
13. J. V. Melo and D. M. Ross, "Minimal residual disease and discontinuationof therapyin chronic myeloid leukemia: can we aim at a cure?" in ASH Education Program Book, pp. 136-142, 2011.
14. F.-X. Mahon, "Is going for cure in chronic myeloid leukemia possible and justifiable?" Hematology/The Education Program of the American Society of Hematology, vol. 2012, pp. 122-128, 2012.
15. E. Paietta, "Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?" Bone Marrow Transplantation, vol. 29, no. 6, pp. 459-465, 2002.
16. J. Goldman and M. Gordon, "Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?" Leukemia & Lymphoma, vol. 47, no. 1, pp. 1-7, 2006.
17. A. Ribas, P. Hersey, M. R. Middleton et al., "New challenges in endpoints for drug development in advanced melanoma", Clinical Cancer Research, vol. 18, no. 2, pp. 336-341, 2012.
18. M. Di Maio, C. Gallo, E. De Maio et al., "Methodological aspects of lung cancer clinical trials in the era of targeted agents", Lung Cancer, vol. 67, no. 2, pp. 127-135, 2010.
19. C. A. Dooms and J. F. Vansteenkiste, "Treatment of patients with advanced non-small cell lung cancer", American Journal of Cancer, vol. 3, no. 5, pp. 281-290, 2004.
20. T. E. Hutson, "Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence", The Oncologist, vol. 16, supplement 2, pp. 14-22, 2011.
21. S. K. Pal and R. A. Figlin, "Targeted therapies for renal cell carcinoma: understanding their impact on survival", Targeted Oncology, vol. 5, no. 2, pp. 131-138, 2010.
22. M. Bilusic and J. L. Gulley, "Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines", Cancer Immunology, Immunotherapy, vol. 61, no. 1, pp. 109-117, 2012.
23. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma", The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
24. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
25. A. Davies, A. Briggs, J. Schneider et al., "The ends justify the mean: outcome measures for estimating the value of new cancer therapies", Health Outcomes Research in Medicine, vol. 3, no. 1, pp. e25-e36, 2012.
26. L. M. Ellis, D. S. Bernstein, E. E. Voest et al., "American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes", Journal of Clinical Oncology, vol. 32, no. 12, pp. 1277-1280, 2014.
27. J. S. De Bono, S. Oudard, and M. Ozguroglu, "Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", The Lancet, vol. 377, no. 9767, pp. 1147-1154, 2010.
28. S. Oudard, A. Joulain, A. De Geer, and O. Sartor, "Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC)", Journal of Clinical Oncology, vol. 29, supplement 7, ASCO, abstract 128, 2011.
29. D. Y.-S. Kuo, S. V. Blank, P. J. Christos et al., "Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study", Gynecologic Oncology, vol. 116, no. 3, pp. 442-446, 2010.
30. J. F. S. Miguel, R. Schlag, N. K. Khuageva et al., "Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma", Journal of Clinical Oncology, vol. 31, no. 4, pp. 448-455, 2013.
31. A. Lopez-Chavez, T. Young, S. Fages et al., "Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis", Journal of Thoracic Oncology, vol. 7, no. 11, pp. 1707-1712, 2012.
32. P. C. Lambert, J. R. Thompson, C. L. Weston, and P. W. Dickman, "Estimating and modeling the cure fraction in populationbased cancer survival analysis", Biostatistics, vol. 8, no. 3, pp. 576-594, 2007.
33. N. R. Smoll, K. Schaller, and O. P. Gautschi, "The cure fraction of glioblastoma multiforme", Neuroepidemiology, vol. 39, no. 1, pp. 63-69, 2012.
34. P. C. Lambert, P. W. Dickman, P. Österlund, T. Andersson, R. Sankila, and B. Glimelius, "Temporal trends in the proportion cured for cancer of the colon and rectum: a populationbased study using data from the Finnish Cancer Registry", International Journal of Cancer, vol. 121, no. 9, pp. 2052-2059, 2007.
35. L. Huang, K. A. Johnson, A. B. Mariotto, J. J. Dignam, and E. J. Feuer, "Population-based survival-cure analysis of ER-negative breast cancer", Breast Cancer Research and Treatment, vol. 123, no. 1, pp. 257-264, 2010.
36. European Medicines Agency Oncology Working Party, "Guideline on the evaluation of anticancer medicinal products in man", 2014, http://www.ema.europa.eu/docs/en GB/document library/Scientific-guideline/2013/01/WC500137128.pdf.
37. National Institute for Health and Clinical Excellence Final Appraisal Determination, "Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma", December 2013, http://www.nice.org.uk/nicemedia/live/12092/61322/61322.pdf.
38. B. Sherrill, J. A. Kaye, R. Sandin, J. C. Cappelleri, and C. Chen, "Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology", OncoTargets and Terapy, vol. 5, pp. 287-296, 2012.
39. J. D. Wolchok, A. Hoos, S. O'Day et al., "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria", Clinical Cancer Research, vol. 15, no. 23, pp. 7412-7420, 2009.
40. A. Hoos, "Evolution of end points for cancer immunotherapy trials", Annals of Oncology, vol. 23, supplement 8, Article ID mds263, pp. viii47-viii52, 2012.
41. P. W. Kantoff, C. S. Higano, N. D. Shore et al., "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", The New England Journal of Medicine, vol. 363, no. 5, pp. 411-422, 2010.
42. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., "Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer", Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099-1105, 2010.
43. G. Bedard, L. Zeng, H. Lam et al., "Meaningful change in oncology quality-of-life instruments: a systematic literature review", Expert Review of Pharmacoeconomics & Outcomes Research, vol. 12, no. 4, pp. 475-483, 2012.